Lupisulin M 50 40IU/ml Injection is a combination insulin preparation containing 50% Insulin Isophane and 50% Human insulin, formulated to provide both intermediate and rapid glycemic control in patients with diabetes mellitus. The intermediate-acting component, Insulin Isophane, ensures prolonged basal insulin coverage, while the soluble Human insulin offers an initial rapid onset of action to manage postprandial glucose excursions effectively. This biphasic insulin suspension is indicated for the treatment of type 1 and type 2 diabetes mellitus when glycemic control cannot be achieved by diet, exercise, and oral hypoglycemic agents alone. Administration is via subcutaneous injection, with dosing individualized based on patient’s metabolic needs, blood glucose monitoring, and response to therapy. Careful titration is essential to minimize the risk of hypoglycemia, the most common adverse effect associated with insulin therapy. Patients should be educated on proper injection technique, storage conditions, and recognition of hypoglycemia symptoms. Lupisulin M 50 40IU/ml Injection should be used under medical supervision, with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes and reduce the risk of diabetes-related complications. It is contraindicated in patients with hypersensitivity to insulin or any excipients in the formulation.